Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe
© 2019, The Author(s). The PROMISE trial enrolled asymptomatic HIV-infected pregnant and postpartum women not eligible for antiretroviral treatment (ART) per local guidelines and randomly assigned proven antiretroviral strategies to assess relative efficacy for perinatal prevention plus maternal/inf...
Saved in:
Main Authors: | L. Stranix-Chibanda, S. Brummel, J. Pilotto, M. Mutambanengwe, V. Chanaiwa, T. Mhembere, M. Kamateeka, J. Aizire, G. Masheto, R. Chamanga, M. Maluwa, S. Hanley, E. Joao, G. Theron, N. Nevrekar, M. Nyati, B. Santos, L. Aurpibul, M. Mubiana-Mbewe, R. Oliveira, T. Anekthananon, P. Mlay, K. Angelidou, C. Tierney, L. Ziemba, A. Coletti, K. McCarthy, M. Basar, N. Chakhtoura, R. Browning, J. Currier, M. G. Fowler, P. Flynn |
---|---|
Other Authors: | FHI 360 |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/51456 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
by: Agwu A., et al.
Published: (2017) -
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
by: Allison L. Agwu, et al.
Published: (2018) -
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
by: Allison L. Agwu, et al.
Published: (2018) -
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial
by: Theodore D. Ruel, et al.
Published: (2022) -
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living with HIV: Week 24 Results from IMPAACT 2014
by: Melvin A.J.
Published: (2023)